EN
  • FR
Contact
  • News
  • Media
  • Health professionals
  • CAREERS
LFB corp
  • The group
    • The LFB group
    • LFB Key dates
    • LFB worldwide
    • A special place in France
    • Governance
      • LFB SA Board of Directors
      • Group Executive Committee
      • LFB BIOMEDICAMENTS
      • LFB BIOTECHNOLOGIES
      • Composition and tasks of the Committees
  • Products and activities
    • Medicinal products
    • Biosafety
    • LFB Research Grant in Immunology
    • The Powers of Blood
  • Innovation
    • Products under development
    • Technology platforms
    • Improving biosafety
  • Responsibilities
    • Rare diseases
    • Relations with patients’ associations
    • A responsible company
    • Transparency of interests for France
  • The LFB group

    LFB is a pharmaceutical group specialising in plasma derived or recombinant therapeutic proteins for the treatment of serious and often rare diseases.

  • LFB Key dates

    Since the creation of LFB in January 1994, discover the dates that gone down the Group's history.

  • LFB worldwide

    Worldwide, LFB has decided on a targeted strategy

  • A special place in France

    LFB has a special place in France, as a player in the healthcare industry with a public health mission

  • Governance

    A public company active in a competitive market

  • Medicinal products

    15 hospital-prescribed medicinal products

  • Biosafety

    Patient safety, a top priority for LFB

  • LFB Research Grant in Immunology

    LFB commits to research in the field of immunology every year.

  • The Powers of Blood

    Our series of 5 educational videos

  • Products under development

    There are several medicinal products at an advanced stage of development, for registration in Europe and the USA

  • Technology platforms

    Two proprietary platforms for therapeutic and technological innovation

  • Improving biosafety

    Innovations to constantly improve the biosafety of medicinal products

  • Rare diseases

    LFB has a continuing commitment to social issues, offering several therapeutic solutions, both currently on sale and under development, for rare diseases

  • Relations with patients’ associations

    LFB is a partner in several patients’ associations and supports projects focused on a better quality of life for patients and their families

  • A responsible company

    LFB’s ethical commitment is reflected in the way it exercises its environmental, social and economic responsibilities

  • Transparency of interests for France

    Transparency of interests for France

Medicinal products
marketed in
40 countries

burger

Home › News

News

Find the latest news and press releases of LFB Group and its companies


27 Jan 2023

Jacques Brom gives you all his best wishes for 2023!

12 Jan 2023
The Powers of Blood: discover the 1st episode of the series
12 Dec 2022
4th vidéo episod : the new LFB Arras plant, November 2022
09 Dec 2022
New LFB anticorruption Code of Conduct
28 Sept 2022
LFB GOVERNANCE CHANGE: Jacques Brom is appointed CEO of LFB
31 Aug 2022
LFB GOVERNANCE CHANGE: LFB BOARD OF DIRECTORS PROPOSES THE APPOINTMENT OF JACQUES BROM AS CHIEF EXECUTIVE OFFICER AND CORINNE FAU AS CHAIRWOMAN OF THE BOARD OF DIRECTORS
25 July 2022
LFB announces the approval of CEVENFACTA® in the European Union
25 May 2022
2022 LFB Corporate video
19 May 2022

Discover the new 2022 LFB corporate Brochure

Read more

Follow us on

  • The group
    • The LFB group
    • LFB Key dates
    • LFB worldwide
    • A special place in France
      • A player in the healthcare industry
      • A public health mission in france
    • Governance
      • Group Executive Committee
      • LFB BIOMEDICAMENTS
      • LFB BIOTECHNOLOGIES
      • Composition and tasks of the Committees
  • The Powers of Blood
  • Products and activities
    • Medicinal products
      • Immunology
      • Haemostasis
      • Intensive care
    • LFB Research Grant in Immunology
    • The Powers of Blood
    • Biosafety
  • Innovation
    • Products under development
    • Technology platforms
      • EMABling®
      • rPRO™ technology
    • Improving biosafety
  • Responsibilities
    • Rare diseases
    • Relations with patients’ associations
    • A responsible company
      • Environmental responsibility
      • Social responsibility
      • Economic responsibility
    • Transparency of interests for France
  • Site map
  • Legal notices
  • Processing of personal data
  • Cookie management policy
  • Cookies management panel
  • Adverse effect reporting
 
 
 

 

×